Sellas Life Sciences has snagged itself a Nasdaq listing by merging with Galena Biopharma. The deal gives Sellas a route to public investors as it seeks to guide its Wilms tumor 1 (WT1)-targeting drug through phase 3 trials in acute myeloid leukemia (AML) and mesothelioma.
New York, N.Y.-based Sellas will be the dominant partner in the combined company, about a third of which will be owned by Galena shareholders. The investors who hung on to stakes in Galena as its downward spiral turned it into a penny stock now get to roll the dice on another cancer vaccine, Sellas’ galinpepimut-S.
The candidate is set to enter phase 3 after coming through mid-phase trials in AML and mesothelioma. For Sellas, the nub of the deal is a Nasdaq listing that can help it fund its R&D ambitions. But its CEO Angelos Stergiou, M.D., Sc.D., also nodded to the assets it will acquire in the deal.
“NeuVax strengthens our platform and may provide important value inflections as the clinical trials progress,” Stergiou said in a statement.
The transaction brings the prolonged death throes of NeuVax-developer Galena to an end, while continuing Sellas’ pivot. Sellas was once a Swiss-Greek biotech best known for striking—and quickly being booted from—an alliance with China’s Fochon Pharmaceutical. But in recent years it has repositioned itself as a global cancer vaccine player by inking a deal with Memorial Sloan Kettering Cancer Center and moving its center of gravity from Europe to New York and Bermuda.
Sellas quietly made the transition, without publicly disclosing financing rounds, with the support of Equilibria Capital, its largest shareholder. Now, it has put itself in the glare of public markets as it seeks to buck the trend in cancer vaccine trials and deliver positive phase 3 data.
By Nick Paul Taylor
Source: Fierce Biotech
Giovanni Caforio, the former CEO of Bristol Myers Squibb, is set to become the next board chairman of Novartis, which on Tuesday proposed the pharmaceutical industry veteran as its pick to replace Joerg Reinhardt in the role next year. Reinhardt has served as Novartis’ chair since 2013 and plans to retire when his 12-year term ends in 2025.
GE HealthCare has raised the curtain on two ultrasound systems equipped with artificial intelligence programs designed to assist in diagnosing conditions in women’s health, including obstetric exams. The Voluson Signature 20 and 18 imaging systems include AI tools capable of automatically identifying and annotating measurements of fetal anatomy.
Scientists from the University of Edinburgh’s School of Chemistry have revealed a new sustainable method of manufacturing complex molecules that could reduce waste produced during drug production. The method published in Nature Chemistry could help to prevent severe side effects caused by drugs that can exist as enantiomers.
